Latest reported dividend
Not available
ABBV · NYSE
Pharmaceutical Preparations
Not available
Not available
Not reported
275.8%
65.4%
These ratios relate cash dividends paid by the company to its earnings and free cash flow for the stated period. They are not dividend yields or measures of a guaranteed future payout.
No matching dividend events have been collected. This does not establish that the company pays no dividend.
| Reporting period | Measure | USD millions | Filing |
|---|---|---|---|
| Dec 31, 2025From Jan 1, 2025 | Operating cash flow | 19,030.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2025From Jan 1, 2025 | Net income | 4,226.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2025From Jan 1, 2025 | Total cash dividends | 11,657.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2025From Jan 1, 2025 | Capital expenditures (PP&E) | 1,214.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2024From Jan 1, 2024 | Operating cash flow | 18,806.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2024From Jan 1, 2024 | Net income | 4,278.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2024From Jan 1, 2024 | Total cash dividends | 11,025.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2024From Jan 1, 2024 | Capital expenditures (PP&E) | 974.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2023From Jan 1, 2023 | Operating cash flow | 22,839.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2023From Jan 1, 2023 | Net income | 4,863.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2023From Jan 1, 2023 | Total cash dividends | 10,539.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2023From Jan 1, 2023 | Capital expenditures (PP&E) | 777.0 | SEC filingFeb 20, 2026 |
| Dec 31, 2022From Jan 1, 2022 | Operating cash flow | 24,943.0 | SEC filingFeb 14, 2025 |
| Dec 31, 2022From Jan 1, 2022 | Net income | 11,836.0 | SEC filingFeb 14, 2025 |
| Dec 31, 2022From Jan 1, 2022 | Total cash dividends | 10,043.0 | SEC filingFeb 14, 2025 |
| Dec 31, 2022From Jan 1, 2022 | Capital expenditures (PP&E) | 695.0 | SEC filingFeb 14, 2025 |
| Dec 31, 2021From Jan 1, 2021 | Operating cash flow | 22,777.0 | SEC filingFeb 20, 2024 |
| Dec 31, 2021From Jan 1, 2021 | Net income | 11,542.0 | SEC filingFeb 20, 2024 |
| Dec 31, 2021From Jan 1, 2021 | Total cash dividends | 9,261.0 | SEC filingFeb 20, 2024 |
| Dec 31, 2021From Jan 1, 2021 | Capital expenditures (PP&E) | 787.0 | SEC filingFeb 20, 2024 |
A higher payout ratio can reflect a larger dividend, lower earnings, or both. Capital spending also affects the FCF denominator. The accounting context matters, especially for financial firms, REITs, and business development companies.
Understand cash payout ratios · Regular vs. special dividendsSource: collected SEC filings. USYieldHub is not affiliated with or endorsed by the SEC or this issuer. Coverage is incomplete; amounts may be unadjusted for splits.